APA

Abdul-Ghani M. A., Puckett C., Triplitt C., Maggs D., Adams J., Cersosimo E. & DeFronzo R. A. (20150924). Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. : Diabetes, obesity & metabolism.

Chicago

Abdul-Ghani M A, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E and DeFronzo R A. 20150924. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. : Diabetes, obesity & metabolism.

Harvard

Abdul-Ghani M. A., Puckett C., Triplitt C., Maggs D., Adams J., Cersosimo E. and DeFronzo R. A. (20150924). Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. : Diabetes, obesity & metabolism.

MLA

Abdul-Ghani M A, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E and DeFronzo R A. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. : Diabetes, obesity & metabolism. 20150924.